InvestmentApr 26, 2026, 05:19 AM
AVLN Files S-1/A for IPO of 11.8M Shares at $16.00-$18.00
AI Summary
Avalyn Pharma Inc. filed an S-1/A for its initial public offering, proposing to offer 11,800,000 shares of common stock at an estimated price range of $16.00 to $18.00 per share. The company expects to raise approximately $181.8 million in net proceeds, which will fund the continued development of its clinical-stage programs AP01 and AP02, and preclinical program AP03. Avalyn Pharma, a clinical-stage biopharmaceutical company, focuses on inhaled therapies for serious, rare respiratory diseases like pulmonary fibrosis, and plans to list on the Nasdaq Global Market under "AVLN."
Key Highlights
- Avalyn Pharma Inc. is offering 11,800,000 shares of common stock in its initial public offering.
- The estimated initial public offering price per share is between $16.00 and $18.00.
- The company has applied to list its common stock on the Nasdaq Global Market under the symbol "AVLN."
- Underwriters have an option to purchase up to an additional 1,770,000 shares.
- Estimated net proceeds from the offering are approximately $181.8 million (or $209.7 million if option exercised).
- Avalyn Pharma is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.
- Net losses were $85.2 million in 2025 and $49.7 million in 2024.
- Accumulated deficit was $265.4 million as of December 31, 2025.